EUCTR2017-000556-26-ES进行中（未招募）1 期
A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Agenus Inc.
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Voluntarily agree to participate by giving written informed consent. Participation in
- •pharmacogenomics testing is optional.
- •2. Be = 18 years of age.
- •3. Diagnosis and prior systemic treatment:
- •a. Phase 1: Have a histologically or cytologically confirmed diagnosis of a metastatic or locally advanced solid tumor for which no standard therapy is available or standard therapy has failed.
- •b. Phase 2:
- •I. Have (1) a histologically or cytologically confirmed diagnosis of squamous-cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix, and (2) metastatic, locally advanced, and/or unresectable disease at the time of enrollment. Histologic confirmation of the original primary tumor is required via pathology report.
- •Note: The following cervical tumors are not eligible: minimal deviation/adenoma malignum, gastric type adenocarcinoma, clear cell carcinoma, and mesonephric carcinoma.
- •II. Has cervical cancer and has relapsed after a platinum-based treatment (first line) regimen for advanced (recurrent, unresectable, or metastatic) disease; Note: Subject receiving chemotherapy concurrently with primary radiation (e.g.,
- •weekly cisplatin) or subject receiving adjuvant chemotherapy following completion of radiation therapy (e.g., paclitaxel and carboplatin for = 4 cycles) and progressed within 6 months after treatment completion will be eligible as this systemic therapy will be considered as first line treatment.
- •4. Measurable disease – based on investigator assessment
- •a. Phase 1: Have objective evidence of disease; the presence of measurable disease is not required.
- •b. Phase 2: Have measurable disease on imaging based on RECIST version 1.1.
- •Note: Subjects must have at least one target lesion to be used to assess response, as defined by RECIST version 1.1. Tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.
- •5. Have a life expectancy of at least 3 months and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •6. Have adequate organ function as indicated by the following laboratory values:
- •a. Adequate hematological function defined by absolute neutrophil count (ANC) = 1.5 x 109/L, platelet count = 100 x 109/L, and stable hemoglobin = 8 g/dL (without transfusions within 1 week before first dose).
- •b. Adequate hepatic function based by a total bilirubin level = 1.5 x the institutional upper limit of normal (IULN), aspartate aminotransferase (AST) level = 2.5 x IULN, alanine aminotransferase (ALT) level = 2.5 x IULN, and alkaline phosphatase = 2.5 x IULN.
- •c. Adequate renal function defined as creatinine = 1.5 x IULN OR calculated creatinine clearance = 50 mL/min for subjects with creatinine levels > 1.5 x IULN (if no local guideline is available, creatinine clearance should be calculated using the Cockcroft- Gault Method).
- •d. Adequate coagulation defined by international normalized ratio (INR) or prothrombin time = 1.5 x I
排除标准
- •1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks before the first dose of treatment.
- •2. Has an inadequate washout period prior to first dose of study drug defined as:
- •a. Received systemic cytotoxic chemotherapy or biological therapy within 3 weeks before first dose,
- •b. Received radiation therapy within 3 weeks before first dose, or
- •c. Had major surgery within 4 weeks before first dose.
- •3. Has received prior therapy with:
- •a. Any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints) such as anti–PD-1, anti–PD-L1, or anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies
- •b. For Phase 2: > 1 systemic treatment regimen for the advanced (recurrent, unresectable, or metastatic) cervical cancer for which the subject is considered for the study
- •Note: In Phase 1, prior treatment with a CTLA-4 antibody is permissible for subjects with metastatic melanoma.
- •4. Has persisting toxicity related to prior therapy of NCI CTCAE Grade > 1 severity.
- •Note: Sensory neuropathy or alopecia of Grade = 2 is acceptable.
- •5. Is expected to require any other form of systemic or localized antineoplastic therapy while on trial (including maintenance therapy with another agent, radiation therapy, and/or surgical resection).
- •6. Has known severe hypersensitivity reactions to fully human monoclonal antibodies (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 [NCI CTCAE] Grade = 3), any history of anaphylaxis, or uncontrolled asthma.
- •7. Is receiving systemic corticosteroid = 7 days prior to the first dose of trial treatment or receiving any other form of systemic immunosuppressive medication (corticosteroid use on study for management of immune-related adverse events, and/or a premedication for IV contrast allergies/reactions is allowed). Subjects who are receiving daily corticosteroid replacement therapy are an exception to this rule. Examples of permitted therapy are daily prednisone at doses of 5 to 7.5 mg or equivalent hydrocortisone dose, and steroid therapy administered by topical, intraocular, intranasal, and/or inhalation routes.
- •8. Has a central nervous system (CNS) tumor, metastasis(es), and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the screening period OR identified prior to consent.
- •Note: Subjects with history of brain metastases that have been treated may participate provided they show evidence of stable supra-tentorial lesions at screening (based on 2 sets of brain images, performed = 4 weeks apart, and obtained after the brain metastases treatment). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be minimal and be expected as sequelae from treated lesions. For individuals who received steroids as part of brain metastases treatment, steroids must be discontinued = 7 days prior to first dose of study drug.
研究者
相似试验
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 20.0Level: LLTClassification code 10008231Term: Cervical cancer recurrentSystem Organ Class: 100000004864EUCTR2017-000556-26-FRAgenus Inc.85
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 21.1Level: LLTClassification code 10008231Term: Cervical cancer recurrentSystem Organ Class: 100000004864EUCTR2017-000556-26-PLAgenus Inc.200
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 20.0Level: LLTClassification code 10008231Term: Cervical cancer recurrentSystem Organ Class: 100000004864EUCTR2017-000556-26-LTAgenus Inc.150
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 20.0 Level: LLT Classification code 10008231 Term: Cervical cancer recurrent System Organ Class: 100000004864EUCTR2017-000556-26-EEAgenus Inc.150
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerEUCTR2017-000556-26-BEAgenus Inc.211